Skip to main content
Immix Biopharma, Inc. logo

Immix Biopharma, Inc. — Investor Relations & Filings

Ticker · IMMX ISIN · US45258H1068 US Manufacturing
Open in API
Filings indexed 218 across all filing types
Latest filing 2026-05-29 Declaration of Voting R…
Country US United States of America
Listing US IMMX

About Immix Biopharma, Inc.

https://immixbio.com/

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for serious diseases. The company's primary strategy is to advance Chimeric Antigen Receptor T-cell (CAR-T) therapies by addressing their key limitation: neurotoxicity. By working to overcome this side effect, ImmixBio aims to expand the use of CAR-T treatments to a wider range of patients, medical centers, and new indications, with a lead program targeting AL Amyloidosis. The company is also developing a novel class of Tissue-Specific Therapeutics (TSTx) for applications in oncology and inflammation.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an SEC Form 8-K reporting the submission of matters to a vote of security holders at the 2026 Annual Meeting. It lists detailed voting results for proposals (election of directors and ratification of auditors). This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-29 English
8-K
Capital/Financing Update Classification · 15% confidence The document is an SEC Form 8-K Current Report under Item 8.01 describing an underwritten offering of common stock, detailing the underwriting agreement, number of shares, pricing, proceeds, closing conditions and related exhibits. This constitutes a capital/financing update rather than an earnings release, management commentary, or regulatory certification. Therefore it matches the Capital/Financing Update category (CAP).
2026-05-21 English
424B5
Share Issue/Capital Change Classification · 89% confidence The document is a prospectus supplement (Form 424B5) for the sale of 16,778,524 shares of common stock, detailing the terms of the offering, underwriting discounts, use of proceeds, risk factors and mechanics of the share issuance. This is not an annual or quarterly report, earnings release, or certification but rather the actual offering documentation for a new share issuance. Under our taxonomy, such filings announcing new share issues belong in the Share Issue/Capital Change category (SHA).
2026-05-21 English
FWP
Share Issue/Capital Change Classification · 85% confidence The document is an Issuer Free Writing Prospectus (Rule 433) announcing the pricing and terms of a $150 million underwritten offering of common stock, i.e., a new share issuance. This is a direct capital-raising announcement relating to a share issue, so it falls under the “Share Issue/Capital Change” category (SHA).
2026-05-21 English
8-K
Regulatory Filings Classification · 85% confidence The document is a Current Report on Form 8-K filed with the SEC, consisting of Regulation FD Disclosure and clinical trial press release updates and exhibits. It does not present full financial statements (10-K, 10-Q or IR), earnings highlights (ER), a proxy or management change notice, nor investor presentation material. It is a general regulatory announcement, so it falls under the fallback category Regulatory Filings (RNS).
2026-05-21 English
10-Q - Immix Biopharma, Inc. (0001873835) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.